Literature DB >> 24327308

Changing pattern of epidemiology in intrahepatic cholangiocarcinoma.

Basile Njei1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24327308     DOI： 10.1002/hep.26958

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  28 in total

1.  A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.

Authors:  Weijing Sun; Anuj Patel; Daniel Normolle; Krishna Patel; James Ohr; James J Lee; Nathan Bahary; Edward Chu; Natalie Streeter; Summer Drummond
Journal:  Cancer       Date:  2018-12-18       Impact factor: 6.860

2.  Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study.

Authors:  Sung Hyun Kim; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2018-08-15       Impact factor: 3.452

3.  Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center Experience of 659 Cases.

Authors:  Shin Hwang; Young-Joo Lee; Gi-Won Song; Kwang-Min Park; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-03-28       Impact factor: 3.452

4.  Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies.

Authors:  Emma E McGee; Sarah S Jackson; Jessica L Petrick; Alison L Van Dyke; Hans-Olov Adami; Demetrius Albanes; Gabriella Andreotti; Laura E Beane-Freeman; Amy Berrington de Gonzalez; Julie E Buring; Andrew T Chan; Yu Chen; Gary E Fraser; Neal D Freedman; Yu-Tang Gao; Susan M Gapstur; J Michael Gaziano; Graham G Giles; Eric J Grant; Francine Grodstein; Patricia Hartge; Mazda Jenab; Cari M Kitahara; Synnove F Knutsen; Woon-Puay Koh; Susanna C Larsson; I-Min Lee; Linda M Liao; Juhua Luo; Roger L Milne; Kristine R Monroe; Marian L Neuhouser; Katie M O'Brien; Ulrike Peters; Jenny N Poynter; Mark P Purdue; Kim Robien; Dale P Sandler; Norie Sawada; Catherine Schairer; Howard D Sesso; Tracey G Simon; Rashmi Sinha; Rachael Stolzenberg-Solomon; Shoichiro Tsugane; Renwei Wang; Elisabete Weiderpass; Stephanie J Weinstein; Emily White; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Xuehong Zhang; Bin Zhu; Katherine A McGlynn; Peter T Campbell; Jill Koshiol
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

5.  Renal metastasis from intrahepatic cholangiocarcinoma.

Authors:  Chihiro Matsumoto; Katsunori Imai; Yosuke Nakao; Rumi Itoyama; Toshihiko Yusa; Shigeki Nakagawa; Hirohisa Okabe; Hidetoshi Nitta; Yo-Ichi Yamashita; Akira Chikamoto; Junji Yatsuda; Tomomi Kamba; Tsuguharu Asato; Yoshiki Mikami; Hideo Baba
Journal:  Int Cancer Conf J       Date:  2020-01-08

6.  Delayed-Phase Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During Conventional Transarterial Chemoembolization.

Authors:  Ruediger Egbert Schernthaner; MingDe Lin; Rafael Duran; Julius Chapiro; Zhijun Wang; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2014-12-05       Impact factor: 2.740

7.  The influence of 18F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma.

Authors:  Youpei Lin; Huanhuan Chong; Guohe Song; Chenhao Zhang; Liangqing Dong; Ling Aye; Fei Liang; Shuaixi Yang; Mengsu Zeng; Guangyu Ding; Shu Zhang; Jieyi Shi; Aiwu Ke; Xiaoying Wang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

8.  Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Authors:  Yu Wang; Xiwei Ding; Shaoqing Wang; Catherine D Moser; Hassan M Shaleh; Essa A Mohamed; Roongruedee Chaiteerakij; Loretta K Allotey; Gang Chen; Katsuyuki Miyabe; Melissa S McNulty; Albert Ndzengue; Emily G Barr Fritcher; Ryan A Knudson; Patricia T Greipp; Karl J Clark; Michael S Torbenson; Benjamin R Kipp; Jie Zhou; Michael T Barrett; Michael P Gustafson; Steven R Alberts; Mitesh J Borad; Lewis R Roberts
Journal:  Cancer Lett       Date:  2016-05-20       Impact factor: 8.679

9.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.

Authors:  Mansi Arora; James M Bogenberger; Amro Abdelrahman; Jennifer L Leiting; Xianfeng Chen; Jan B Egan; Aradhana Kasimsetty; Elzbieta Lenkiewicz; Smriti Malasi; Pedro Luiz Serrano Uson; Bolni Marius Nagalo; Yumei Zhou; Marcela A Salomao; Heidi E Kosiorek; Esteban Braggio; Michael T Barrett; Mark J Truty; Mitesh J Borad
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-21       Impact factor: 3.288

10.  WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.

Authors:  Luke Boulter; Rachel V Guest; Timothy J Kendall; David H Wilson; Davina Wojtacha; Andrew J Robson; Rachel A Ridgway; Kay Samuel; Nico Van Rooijen; Simon T Barry; Stephen J Wigmore; Owen J Sansom; Stuart J Forbes
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.